Jazz Pharmaceuticals (JAZZ) Deferred Taxes (2012 - 2026)
Jazz Pharmaceuticals' quarterly Deferred Taxes came in at -$66.2 million in Q1 2026, down 51.14% year-on-year from -$135.5 million in Q1 2025, and down 4.57% quarter-over-quarter from -$63.3 million in Q4 2025.
Jazz Pharmaceuticals has reported Deferred Taxes for 15 years, with the latest figure at -$66.2 million in Q1 2026.
- For the quarter ending Q1 2026, Deferred Taxes fell 51.14% year-over-year to -$66.2 million; the trailing twelve-month figure through Mar 2026 stood at -$467.4 million (down 151.62% YoY), and the FY2025 full-year result was -$445.0 million, down 113.59% from the prior year.
- Deferred Taxes for Q1 2026 stood at -$66.2 million, down from -$63.3 million in the prior quarter.
- The five-year high for Deferred Taxes was -$2.4 million in Q4 2024, with the low at -$271.4 million in Q3 2025.
- Average Deferred Taxes over 5 years is -$74.8 million, with a median of -$66.1 million recorded in 2023.
- Year-over-year, Deferred Taxes soared 93.44% in 2024 and sank 2588.28% in 2025.
- Tracing JAZZ's Deferred Taxes over 5 years: stood at -$145.4 million in 2022, then soared by 75.31% to -$35.9 million in 2023, then soared by 93.44% to -$2.4 million in 2024, then slumped by 2588.28% to -$63.3 million in 2025, then slipped by 4.57% to -$66.2 million in 2026.
- The last three Deferred Taxes figures came in at -$66.2 million (Q1 2026), -$63.3 million (Q4 2025), and -$271.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | -66.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.20 Mn |
| Dec 31, 2025 | -63.31 Mn |
| Sep 30, 2025 | -271.41 Mn |
| Jun 30, 2025 | -66.45 Mn |
| Mar 31, 2025 | -43.80 Mn |
| Dec 31, 2024 | -2.36 Mn |
| Sep 30, 2024 | -64.40 Mn |
| Jun 30, 2024 | -75.18 Mn |
| Mar 31, 2024 | -66.39 Mn |
| Dec 31, 2023 | -35.90 Mn |
| Sep 30, 2023 | -78.92 Mn |
| Jun 30, 2023 | -79.33 Mn |
| Mar 31, 2023 | -66.06 Mn |
| Dec 31, 2022 | -145.38 Mn |
| Sep 30, 2022 | -64.56 Mn |
| Jun 30, 2022 | -36.98 Mn |
| Mar 31, 2022 | -45.34 Mn |
| Dec 31, 2021 | -27.40 Mn |
| Sep 30, 2021 | -74.99 Mn |
| Jun 30, 2021 | 190.70 Mn |
| Mar 31, 2021 | -19.11 Mn |
| Dec 31, 2020 | -16.03 Mn |
| Sep 30, 2020 | -38.14 Mn |
| Jun 30, 2020 | -18.79 Mn |
| Mar 31, 2020 | -63.98 Mn |
| Dec 31, 2019 | -68.68 Mn |
| Sep 30, 2019 | -16.59 Mn |
| Jun 30, 2019 | -134.29 Mn |
| Mar 31, 2019 | -17.05 Mn |
| Dec 31, 2018 | -44.16 Mn |
| Sep 30, 2018 | -12.43 Mn |
| Jun 30, 2018 | -16.92 Mn |
| Mar 31, 2018 | -15.31 Mn |
| Dec 31, 2017 | -172.23 Mn |
| Sep 30, 2017 | -23.40 Mn |
| Jun 30, 2017 | -14.96 Mn |
| Mar 31, 2017 | -15.00 Mn |
| Dec 31, 2016 | -11.89 Mn |
| Sep 30, 2016 | -19.16 Mn |
| Jun 30, 2016 | -4.37 Mn |
| Mar 31, 2016 | -5.74 Mn |
| Dec 31, 2015 | -42.99 Mn |
| Sep 30, 2015 | -8.50 Mn |
| Jun 30, 2015 | -7.61 Mn |
| Mar 31, 2015 | -9.26 Mn |
| Dec 31, 2014 | -13.01 Mn |
| Sep 30, 2014 | -17.65 Mn |
| Jun 30, 2014 | -14.22 Mn |
| Mar 31, 2014 | -4.38 Mn |
| Sep 30, 2013 | -17.96 Mn |
| Jun 30, 2013 | -9.06 Mn |
| Mar 31, 2013 | -3.87 Mn |
| Dec 31, 2012 | -105.09 Mn |
| Sep 30, 2012 | -8.77 Mn |